首页> 美国卫生研究院文献>International Journal of Molecular Sciences >The Expression Profile of mRNA and tRNA Genes in Splenocytes and Neutrophils after In Vivo Delivery of Antitumor Short Hairpin RNA of Indoleamine 23- Dioxygenase
【2h】

The Expression Profile of mRNA and tRNA Genes in Splenocytes and Neutrophils after In Vivo Delivery of Antitumor Short Hairpin RNA of Indoleamine 23- Dioxygenase

机译:在吲哚胺23-二氧化酶抗肿瘤短发夹RNA体内脾细胞和中性粒细胞中mRNA和TRNA基因的表达分布

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

RNA-based therapeutics are considered as novel treatments for human diseases. Our previous study demonstrated that treatment with short-hairpin RNA against Ido1 (IDO shRNA) suppresses tumor growth, detects Th1-bias immune responses, and elevates expression of tryptophan transfer RNA (tRNATrp) in total splenocytes. In addition, depletion of Ly6g+ neutrophils attenuates the effect of IDO shRNA. The aim of this study was to investigate the regulatory network and the expression profile of tRNAs and other non-coding RNAs in IDO shRNA-treated spleens. The total splenocytes and magnetic bead-enriched splenic neutrophils were collected from the lung tumor bearing mice, which were treated with IDO shRNA or scramble IDO shRNA, and the collected cells were subsequently subjected to RNA sequencing. The gene ontology analysis revealed the different enrichment pathways in total splenocytes and splenic neutrophils. Furthermore, the expression of tRNA genes was identified and validated. Six isoacceptors of tRNA, with different expression patterns between total splenocytes and splenic neutrophils, were observed. In summary, our findings not only revealed novel biological processes in IDO shRNA-treated total splenocytes and splenic neutrophils, but the identified tRNAs and other non-coding RNAs may contribute to developing a novel biomarker gene set for evaluating the clinical efficiency of RNA-based cancer immunotherapies.
机译:基于RNA的治疗剂被认为是对人类疾病的新型治疗方法。我们以前的研究表明,用短发夹RNA对IDO1(IDO ShRNA)的处理抑制肿瘤生长,检测Th-偏置免疫应答,并提高色氨酸转移RNA(Trnatrp)在总脾细胞中的表达。此外,Ly6G +中性粒细胞的耗竭衰减IDO ShRNA的效果。本研究的目的是研究监管网络和TrNAS和其他非编码RNA的表达谱系在IDO ShRNA治疗的脾脏中。从肺肿瘤轴承小鼠收集总脾细胞和磁性珠烯酸嗜中性粒细胞,其用IDO shRNA或扰荷IDO shRNA处理,随后将收集的细胞进行RNA测序。基因本体分析显示了总脾细胞和脾中性粒细胞的不同富集途径。此外,鉴定并验证了TRNA基因的表达。 TRNA的六个异征剂,在总脾细胞和脾中性粒细胞之间具有不同的表达模式。总之,我们的发现不仅揭示了IDO shRNA处理的总脾细胞和脾中性粒细胞的新型生物过程,但所鉴定的TrNA和其他非编码RNA可能有助于开发一种用于评估RNA的临床效率的新型生物标志物基因癌症免疫治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号